•  
  •  
 

Subject Area

Internal Medicine

Article Type

Original Study

Abstract

Objectives: to assess the effectiveness of systemic immune-inflammation index (SII), red blood cell distribution width (RDW), and their combination in predicting Hepatocellular carcinoma (HCC) patient survival. Background: HCC is among the most prevalent cancers and the third leading cause of cancer-related deaths worldwide. The SII and RDW are markers of chronic inflammation calculable from a complete blood count (CBC). Methods: an observational prospective study conducted on 60 newly diagnosed HCC patients. Patients were followed every 3 months for a year, with clinical, laboratory (SII and RDW), data recorded at baseline, 3, 6, and 9 months. Results: In this study, we compared the demographic and clinical characteristics between HCC patients who were alive and those who had died. Males were predominant in both groups (72.7% alive vs. 88.9% dead), and the mean age was slightly higher in the dead group (63.11 ± 6.81 years vs. 61.78 ± 6.08 years). A significant difference was noted on the receipt of direct-acting antiviral agents (DAAs), with 93.9% of the alive group receiving DAAs compared to 66.7% of the dead group (P=0.007). Additionally, SII and RDW-CV showed a significant increase in the dead group at 3, 6, 9 months indicating their potential as prognostic markers Conclusions: HCC patients with elevated SII and RDW values are associated with poor overall survival compared to those with lower values.

Download

Share

COinS